Greenberg Richard S 4
4 · NEXIEN BIOPHARMA, INC. · Filed Oct 29, 2018
Insider Transaction Report
Form 4
Greenberg Richard S
DirectorEVP and Chairman10% Owner
Transactions
- Award
Options to purchase common stock (right to buy)
2018-10-26+100,000→ 100,000 totalExercise: $0.66From: 2018-10-26Exp: 2025-10-26→ Common Stock (100,000 underlying)
Holdings
- 888,000
Common Stock
- 150,000
Options to purchase common stock (right to buy)
Exercise: $0.54From: 2018-07-25Exp: 2025-07-25→ Common Stock (150,000 underlying)
Footnotes (2)
- [F1]Granted under the Company's 2018 Equity Incentive Plan.
- [F2]37,500 options vested immediately, with the remainder vesting quarterly over the next 6 quarters beginning with the quarter ending September 30, 2018.